دورية أكاديمية
أعرض في EDS

Design, physicochemical characterisation, and in vitro cytotoxicity of cisplatin-loaded PEGylated chitosan injectable nano / sub-micron crystals.

التفاصيل البيبلوغرافية
العنوان: Design, physicochemical characterisation, and in vitro cytotoxicity of cisplatin-loaded PEGylated chitosan injectable nano / sub-micron crystals.
المؤلفون: Sultan MH; Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia., Moni SS; Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia., Alqahtani SS; Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.; Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan, Saudi Arabia., Ali Bakkari M; Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia., Alshammari A; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Almoshari Y; Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia., Alshahrani S; Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia., Madkhali OA; Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia., Mohan S; Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia.
المصدر: Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society [Saudi Pharm J] 2023 Jun; Vol. 31 (6), pp. 861-873. Date of Electronic Publication: 2023 Apr 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Saudi Pharmaceutical Society Country of Publication: Saudi Arabia NLM ID: 9705695 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1319-0164 (Print) Linking ISSN: 13190164 NLM ISO Abbreviation: Saudi Pharm J Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Riyadh : Saudi Pharmaceutical Society
Original Publication: Riyadh, Kingdom of Saudi Arabia : The Society,
مستخلص: The study aimed to develop cisplatin-loaded PEGylated chitosan nanoparticles. The optimal batch of cisplatin-loaded PEGylated chitosan nanoparticles had a + 49.9 mV zeta potential, PDI of 0.347, and % PDI of 58.9. Nanoparticle zeta size was 741.4 z. d.nm, the size in diameter was 866.7 ± 470.5 nm, and nanoparticle conductivity in colloidal solution was 0.739 mS/cm. Differential scanning calorimetry (DSC) revealed that cisplatin-loaded PEGylated chitosan nanoparticles had sharp endothermic peaks at temperatures at 168.6 °C. The thermogravimetric analysis (TGA) showed the weight loss of cisplatin-loaded PEGylated chitosan nanoparticles, which was observed as 95% at 262.76 °C. XRD investigation on cisplatin-loaded PEGylated chitosan nanoparticles exhibited distinct peaks at 2θ as 9.7°, 20.4°, 22.1°, 25.3°, 36.1°, 38.1°, 39.5°, 44.3°, and 64.5°, confirming crystalline structure. The 1 H NMR analysis showed the fingerprint region of cisplatin-loaded PEGylated chitosan nanoparticles as 0.85, 1.73, and 1.00 ppm in the proton dimension and de-shielded proton peaks appeared at 3.57, 3.58, 3.58, 3.59, 3.65, 3.67, 3,67, 3,67, 3.70, 3.71, 3.77, 3.78 and 4.71 ppm. The 13 C NMR spectrum showed specified peaks at 63.18, 69.20, and 70.77 ppm. The FT-IR spectra of cisplatin loaded PEGylated nanoparticles show the existence of many fingerprint regions at 3186.52, 2931.68, 1453.19, 1333.98, 1253.71, 1085.19, 1019.60, 969.98, 929.53, 888.80, 706.13, and 623.67 cm -1 . The drug release kinetics of cisplatin loaded PEGylated chitosan nanoparticles showed zero order kinetics with 48% of drug release linearity fashion which has R 2 value of 0.9778. Studies on the MCF-7 ATCC human breast cancer cell line in vitro revealed that the IC50 value 82.08 µg /mL. Injectable nanoparticles had good physicochemical and cytotoxic properties. This method is novel since the application of the PEGylation processes leads to an increased solubility of chitosan nanoparticles at near neutral pH.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2023 The Author(s).)
References: Carbohydr Polym. 2020 Dec 15;250:116891. (PMID: 33049828)
Carcinogenesis. 2014 May;35(5):1100-9. (PMID: 24379240)
ACS Appl Mater Interfaces. 2018 Oct 10;10(40):33945-33955. (PMID: 30212622)
Sci Rep. 2021 May 10;11(1):9914. (PMID: 33972626)
Nano Today. 2015 Aug;10(4):487-510. (PMID: 26640510)
Asian Pac J Cancer Prev. ;18(9):2329-2337. (PMID: 28950674)
J Pharm Biomed Anal. 2003 Aug 21;32(6):1149-58. (PMID: 12907258)
Adv Drug Deliv Rev. 2018 Jul;132:81-103. (PMID: 30059703)
Front Pharmacol. 2013 Mar 14;4:28. (PMID: 23504227)
Pharmaceutics. 2022 Feb 13;14(2):. (PMID: 35214139)
Polymers (Basel). 2017 Oct 04;9(10):. (PMID: 30965789)
Methods Mol Biol. 2011;697:63-70. (PMID: 21116954)
Adv Pharm Bull. 2017 Sep;7(3):339-348. (PMID: 29071215)
Molecules. 2017 Oct 05;22(10):. (PMID: 28981459)
J Nanobiotechnology. 2018 Sep 19;16(1):71. (PMID: 30231877)
Molecules. 2022 Dec 01;27(23):. (PMID: 36500493)
Int J Biol Macromol. 2023 Jan 1;224:797-809. (PMID: 36283555)
Adv Drug Deliv Rev. 2010 Jan 31;62(1):59-82. (PMID: 19925837)
ACS Omega. 2020 Aug 06;5(32):20224-20230. (PMID: 32832775)
Sci Rep. 2022 Jan 10;12(1):468. (PMID: 35013493)
Regul Toxicol Pharmacol. 2010 Apr;56(3):290-9. (PMID: 19788905)
Data Brief. 2016 Apr 04;7:1228-1236. (PMID: 28795121)
J Microencapsul. 2015;32(6):578-88. (PMID: 26218628)
Carbohydr Polym. 2022 Feb 1;277:118869. (PMID: 34893274)
Int J Nanomedicine. 2011;6:1977-90. (PMID: 21976974)
Carbohydr Polym. 2022 Nov 1;295:119878. (PMID: 35989018)
Adv Pharm Bull. 2017 Sep;7(3):427-432. (PMID: 29071225)
Curr Drug Metab. 2009 Oct;10(8):836-41. (PMID: 20214578)
Biomacromolecules. 2000 Winter;1(4):609-14. (PMID: 11710189)
Adv Drug Deliv Rev. 2016 Feb 1;97:280-301. (PMID: 26686425)
Oncogene. 2012 Apr 12;31(15):1869-83. (PMID: 21892204)
Chem Soc Rev. 2017 Jul 17;46(14):4218-4244. (PMID: 28585944)
Pharmaceutics. 2020 Mar 07;12(3):. (PMID: 32156022)
ACS Nano. 2015 Sep 22;9(9):8655-71. (PMID: 26256227)
J Pharm (Cairo). 2013;2013:812387. (PMID: 26555995)
Curr Pharm Biotechnol. 2020;21(8):659-666. (PMID: 31886748)
Eur J Pharmacol. 2014 Oct 5;740:364-78. (PMID: 25058905)
Int J Nanomedicine. 2006;1(2):181-7. (PMID: 17722534)
Food Chem Toxicol. 2009 Jun;47(6):1176-1183. (PMID: 19425235)
فهرسة مساهمة: Keywords: Cancer; Cisplatin; Cytotoxicity; Nanoparticles; Pegylated Chitosan; Polydispersity Index; Size; Zetapotential
تواريخ الأحداث: Date Created: 20230525 Latest Revision: 20230528
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10203781
DOI: 10.1016/j.jsps.2023.04.005
PMID: 37228326
قاعدة البيانات: MEDLINE
الوصف
تدمد:1319-0164
DOI:10.1016/j.jsps.2023.04.005